Manufacturer of Controlled Substances; Notice of Application, 33785 [2011-14253]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 111 / Thursday, June 9, 2011 / Notices
The company plans to import these
controlled substances for the
manufacture of reference standards.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 11, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in Schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Drug
I
I
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 8, 2011.
I
I
I
I
Dated: June 1, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Manufacturer of Controlled
Substances; Notice of Application
Methcathinone (1237) ..................
N-ethylamphetamine (1475) .........
N,N-dimethylamphetamine (1480)
4-methylaminorex (cis isomer)
(1590).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2,5-dimethoxy-4-(n)propylthiophenethylamine.
(7348) ...........................................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-bromo-2,5-dimethoxy-amphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4-methyl-2,5-dimethoxy-amphetamine (7395).
2,5-dimethoxyamphetamine
(7396).
2,5-dimethoxy-4ethylamphetamine (7399).
3,4-methylenedioxy amphetamine
(7400).
N-hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-methylenedioxy-Nethylamphetamine (7404).
3,4methylenedioxymethamphetamine (MDMA) (7405).
4-methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-methoxy-N,Ndiisopropyltryptamine (7439).
N-ethyl-1-phenylcyclohexylamine
(7455).
1-(1-phenylcyclohexyl)-pyrrolidine
(7458).
1-[1-(2-thienyl)-cyclohexyl]-piperidine (7470).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Methamphetamine (1105) ............
1-phenylcyclohexylamine (7460) ..
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1-piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Noroxymorphone (9668) ..............
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 28, 2011,
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
Dated: June 1, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–14255 Filed 6–8–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug Enforcement Administration
VerDate Mar<15>2010
19:07 Jun 08, 2011
Jkt 223001
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
33785
I
I
I
I
[FR Doc. 2011–14253 Filed 6–8–11; 8:45 am]
I
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
Federal Bureau of Investigation
I
Notice of Charter Reestablishment
I
In accordance with the provisions of
the Federal Advisory Committee Act,
Title 5, United States Code, Appendix,
and Title 41, Code of Federal
Regulations, Section 101–6.1015, with
the concurrence of the Attorney
General, I have determined that the
reestablishment of the Criminal Justice
Information Services (CJIS) Advisory
Policy Board (APB) is in the public
interest. In connection with the
performance of duties imposed upon the
FBI by law, I hereby give notice of the
reestablishment of the APB Charter.
The APB provides me with general
policy recommendations with respect to
the philosophy, concept, and
operational principles of the various
criminal justice information systems
managed by the FBI’s CJIS Division.
The APB includes representatives
from local and state criminal justice
agencies; Tribal law enforcement
representatives; members of the judicial,
prosecutorial, and correctional sectors
of the criminal justice community, as
well as one individual representing a
national security agency; a
representative of Federal agencies
participating in the CJIS Division
Systems; and representatives of criminal
justice professional associations (i.e.,
the American Probation and Parole
Association; American Society of Crime
Laboratory Directors, Inc.; International
Association of Chiefs of Police; National
District Attorneys’ Association; National
Sheriffs’ Association; Major Cities
Chiefs’ Association; Major County
Sheriffs’ Association; and a
representative from a national
professional association representing
the courts or court administrators
nominated by the Conference of Chief
Justices). The Attorney General has
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
E:\FR\FM\09JNN1.SGM
09JNN1
]]>Agencies
[Federal Register Volume 76, Number 111 (Thursday, June 9, 2011)]
[Notices]
[Page 33785]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-14253]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 28, 2011, Alltech
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methcathinone (1237)....................... I
N-ethylamphetamine (1475).................. I
N,N-dimethylamphetamine (1480)............. I
4-methylaminorex (cis isomer) (1590)....... I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2,5-dimethoxy-4-(n)-
propylthiophenethylamine.
(7348)..................................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-bromo-2,5-dimethoxy-amphetamine (7391)... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-methyl-2,5-dimethoxy-amphetamine (7395).. I
2,5-dimethoxyamphetamine (7396)............ I
2,5-dimethoxy-4-ethylamphetamine (7399).... I
3,4-methylenedioxy amphetamine (7400)...... I
N-hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-methylenedioxy-N-ethylamphetamine I
(7404).
3,4-methylenedioxymethamphetamine (MDMA) I
(7405).
4-methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-methoxy-N,N-diisopropyltryptamine (7439). I
N-ethyl-1-phenylcyclohexylamine (7455)..... I
1-(1-phenylcyclohexyl)-pyrrolidine (7458).. I
1-[1-(2-thienyl)-cyclohexyl]-piperidine I
(7470).
Dihydromorphine (9145)..................... I
Normorphine (9313)......................... I
Methamphetamine (1105)..................... II
1-phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
1-piperidinocyclohexane-carbonitrile (8603) II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Ecgonine (9180)............................ II
Meperidine intermediate-B (9233)........... II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical applications only in clinical, toxicological, and
forensic laboratories.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR Sec. 1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 8, 2011.
Dated: June 1, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-14253 Filed 6-8-11; 8:45 am]
BILLING CODE 4410-09-P
